Semaglutide Injections for Weight Loss
Mason, Ohio
Regenerative Aesthetics offers medically supervised semaglutide weight management in Mason, Ohio for appropriate adults seeking additional support with weight loss and long-term weight management.
Semaglutide belongs to a class of medications called GLP-1 receptor agonists. When used for chronic weight management in an appropriate patient, semaglutide can help regulate appetite, reduce calorie intake, and increase feelings of fullness as part of a treatment plan that also includes nutrition, physical activity, and ongoing medical care.
Treatment begins with an individualized medical evaluation. Your health history, medications, weight-related conditions, previous weight-loss efforts, treatment goals, and potential risk factors are reviewed before determining whether semaglutide is an appropriate option.
Regenerative Aesthetics welcomes patients from Mason, Cincinnati, West Chester, Deerfield Township, and surrounding Southwest Ohio communities.
What Is Semaglutide?
Semaglutide is a glucagon-like peptide-1, or GLP-1, receptor agonist.
GLP-1 is involved in the regulation of appetite and calorie intake. Semaglutide activates GLP-1 receptors and can help reduce hunger and increase feelings of fullness, which may make it easier for appropriate patients to consume fewer calories.
Semaglutide is used in different FDA-approved medications for different medical indications. WEGOVY® contains semaglutide and is FDA-approved for chronic weight management in appropriate patients, while other semaglutide-containing medications have different approved indications.
For this reason, the specific medication, formulation, dose, and treatment plan should always be determined by a qualified medical provider.
How Does Semaglutide Help With Weight Loss?
Semaglutide acts on GLP-1 receptors involved in appetite regulation.
For many appropriate patients, treatment can reduce hunger, increase satiety after eating, and help reduce overall calorie intake.
Weight loss does not occur because semaglutide directly “burns fat.” Instead, the medication supports physiological pathways involved in appetite and food intake.
Semaglutide works best as part of a comprehensive medical weight-management plan that includes appropriate nutrition, physical activity, behavioral changes, and regular medical follow-up.
Who May Be a Candidate for Semaglutide Weight Management?
Adults With Obesity
FDA-approved semaglutide for chronic weight management may be appropriate for adults with obesity when used together with a reduced-calorie diet and increased physical activity.
Adults With Overweight and Weight-Related Conditions
Treatment may also be appropriate for adults who have overweight together with at least one weight-related medical condition.
Examples may include hypertension, dyslipidemia, cardiovascular disease, or other clinically relevant weight-related conditions.
Patients Seeking Medically Supervised Weight Management
Semaglutide should be part of a medically supervised treatment plan rather than used as a stand-alone solution for weight loss.
Your provider will review your medical history, medications, previous weight-loss attempts, treatment goals, and individual risk factors before determining whether treatment is appropriate.
Reduced Appetite
Semaglutide acts on GLP-1 receptors involved in appetite regulation and may help appropriate patients experience less hunger during treatment.
Greater Feelings of Fullness
Treatment may help patients feel satisfied with smaller amounts of food, supporting reduced calorie intake as part of a structured weight-management program.
Clinically Meaningful Weight Reduction
Clinical trials of FDA-approved semaglutide 2.4 mg used together with lifestyle intervention demonstrated significant average weight reduction in appropriate adults with overweight or obesity.
Individual results vary, and results from clinical trials should not be interpreted as a guarantee of a specific amount of weight loss.
Long-Term Weight Management
Weight management is an ongoing medical process. Semaglutide may be used as part of a long-term strategy when treatment remains appropriate, effective, and well tolerated.
Medical Monitoring
Regular follow-up allows your provider to evaluate treatment response, side effects, nutrition, activity, medications, and changes in your health while determining whether the treatment plan should be adjusted.
FDA-approved WEGOVY® injection is administered subcutaneously once weekly.
The injection may be given in the abdomen, thigh, or upper arm according to the product instructions.
Treatment typically begins at a lower dose and is increased gradually according to the approved dosing schedule and individual tolerability. Gradual dose escalation is used in part to help reduce gastrointestinal adverse reactions.
Patients should follow the exact medication, dose, injection technique, and schedule prescribed by their healthcare provider. Do not increase the dose or inject more frequently unless specifically instructed by your medical provider.
Why Does the Semaglutide Dose Increase Gradually?
Semaglutide treatment is generally started at a lower dose and gradually increased rather than beginning immediately at the maintenance dose.
This titration process allows the body to adapt to treatment and is intended to reduce the likelihood or severity of gastrointestinal side effects.
Your provider will determine the appropriate dosing schedule based on the medication being prescribed, current prescribing information, treatment response, and tolerability.
A dose should not be increased simply because weight loss appears slower than expected.
How Much Weight Can I Lose With Semaglutide?
The amount of weight lost during semaglutide treatment varies substantially from one patient to another.
Factors that may influence results include starting weight, medication dose, duration of treatment, nutrition, physical activity, other medical conditions, medications, treatment adherence, and individual biological response.
In a major clinical trial of adults with overweight or obesity without diabetes, participants receiving semaglutide 2.4 mg together with lifestyle intervention lost an average of approximately 14.9% of their starting body weight at 68 weeks.
This is an average clinical-trial result rather than a prediction of individual outcome. Some patients lost more, some lost less, and some discontinued treatment.
How Long Does Semaglutide Treatment Take?
Semaglutide should not be viewed as a short-term rapid weight-loss treatment.
Weight reduction generally develops progressively over time as treatment is titrated and continued together with appropriate lifestyle changes.
The duration of treatment depends on individual response, tolerance, treatment goals, health status, and whether your provider determines that continued therapy remains appropriate.
Because obesity is a chronic medical condition, some appropriate patients may require ongoing weight-management treatment rather than a short course followed by permanent discontinuation.
What Happens If I Stop Semaglutide?
Weight regain may occur after semaglutide is discontinued, particularly if appetite increases again after treatment ends.
For this reason, long-term weight-management planning is important throughout treatment.
Nutrition, physical activity, behavioral strategies, medical follow-up, and an individualized maintenance plan can all play a role in supporting weight management if medication is reduced or discontinued.
Never stop or change prescription treatment without discussing the plan with your healthcare provider.
What Are the Common Side Effects of Semaglutide?
Gastrointestinal side effects are among the most frequently reported reactions with semaglutide used for weight management.
Common reactions associated with FDA-approved WEGOVY® include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion, dizziness, abdominal bloating, belching, flatulence, gastroenteritis, and gastroesophageal reflux disease.
Side effects may be more noticeable during dose escalation and may improve as the body adjusts to treatment.
Contact your medical provider if symptoms are severe, persistent, or interfere with hydration or nutrition.
Important Risks and Safety Information
Semaglutide is a prescription medication and is not appropriate for everyone.
The current prescribing information includes warnings and precautions involving acute pancreatitis, gallbladder disease, hypoglycemia in certain patients, acute kidney injury related to volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions, diabetic retinopathy complications in patients with type 2 diabetes, increased heart rate, and pulmonary aspiration during general anesthesia or deep sedation.
Patients should tell their healthcare provider about all medications and medical conditions before beginning treatment.
Because semaglutide delays gastric emptying, patients should also tell medical and anesthesia providers that they are taking semaglutide before planned surgery or procedures requiring anesthesia or deep sedation.
Who Should Not Use Semaglutide?
WEGOVY® is contraindicated in patients with a personal or family history of medullary thyroid carcinoma, also called MTC, and in patients with Multiple Endocrine Neoplasia syndrome type 2, or MEN 2.
It is also contraindicated in patients with a known serious hypersensitivity to semaglutide or any of the product components.
Semaglutide should not be used during pregnancy for weight reduction. Patients planning pregnancy should discuss treatment with their healthcare provider in advance because semaglutide has a long elimination period.
A complete medical evaluation is necessary to identify additional conditions or medications that may affect whether treatment is appropriate.
Semaglutide and Pregnancy
Weight-loss treatment with semaglutide is not appropriate during pregnancy.
Patients who become pregnant while receiving semaglutide for weight management should contact their healthcare provider.
Because semaglutide remains in the body for an extended period, the prescribing information recommends discontinuing WEGOVY® at least two months before a planned pregnancy.
Tell your provider if you are pregnant, planning pregnancy, breastfeeding, or may become pregnant before beginning treatment.
Semaglutide and Other GLP-1 Medications
Patients should provide a complete list of medications before beginning semaglutide treatment.
FDA-approved WEGOVY® should not be used together with another semaglutide-containing product or another GLP-1 receptor agonist unless specifically supported by current prescribing guidance.
Do not combine, alternate, or change GLP-1 medications on your own.
If you are already using a medication such as Ozempic®, Wegovy®, or another GLP-1-based treatment, tell your provider before starting a medical weight-management program.
FDA-Approved vs. Compounded Semaglutide
FDA-approved semaglutide medications and compounded semaglutide products are not the same from a regulatory standpoint.
FDA-approved medications undergo FDA review for safety, effectiveness, quality, manufacturing, labeling, and dosing. Compounded drugs are not FDA-approved and do not undergo the same premarket review.
The FDA states that compounded medications should generally be used only when a patient’s medical needs cannot be met by an available FDA-approved drug.
If a compounded medication is being considered, patients should understand exactly what product is being prescribed, its concentration, how the dose is measured, where it is obtained, and how it should be administered.
Why Medical Supervision Matters
Semaglutide treatment involves more than receiving a weekly injection.
Medical supervision helps determine whether treatment is appropriate, select an appropriate medication and dosing plan, monitor side effects, identify medication interactions, evaluate treatment response, and make adjustments when necessary.
Your weight-management plan should also consider nutrition, physical activity, sleep, metabolic health, existing medical conditions, medications, and sustainable long-term habits.
Regular follow-up provides an opportunity to evaluate both weight-related progress and overall health rather than focusing only on the number on the scale.
Personalized Medical Weight Management in Mason, Ohio
At Regenerative Aesthetics, medical weight management begins with an individualized evaluation rather than a one-size-fits-all prescription.
Your provider reviews your weight history, current health, medications, previous weight-loss efforts, weight-related conditions, treatment goals, and potential contraindications before recommending a treatment strategy.
When semaglutide is medically appropriate, ongoing monitoring helps assess tolerability, response, and whether treatment adjustments are needed.
Our goal is to support sustainable weight management through appropriate medical treatment combined with practical lifestyle strategies and ongoing clinical care.
Why Choose Regenerative Aesthetics for Semaglutide Weight Management in Mason, Ohio?
Regenerative Aesthetics provides medically supervised weight management for appropriate patients in Mason, Ohio.
Our approach emphasizes individualized medical evaluation, responsible prescribing, appropriate dose progression, regular follow-up, and realistic expectations regarding weight-loss results.
Weight management can be influenced by multiple factors including metabolic health, hormonal changes, medications, nutrition, activity, sleep, and other medical conditions. These factors are considered when developing an individualized plan.
We welcome patients from Mason, Cincinnati, West Chester, Deerfield Township, and surrounding Southwest Ohio communities.
Frequently Asked Questions About Semaglutide for Weight Loss
How does semaglutide help with weight loss?
Semaglutide activates GLP-1 receptors involved in appetite regulation. It can reduce hunger, increase feelings of fullness, and help decrease calorie intake in appropriate patients.
How often are semaglutide injections given?
FDA-approved WEGOVY® injection is administered once weekly. Patients should follow the exact dosing schedule prescribed for their specific medication.
How much weight can I lose with semaglutide?
Results vary considerably. In a major clinical trial of semaglutide 2.4 mg together with lifestyle intervention, adults without diabetes lost an average of approximately 14.9% of their starting body weight over 68 weeks. Clinical-trial averages do not predict an individual patient's results.
How quickly will I lose weight?
Weight loss generally occurs gradually over time. Early treatment includes dose escalation, and individual response varies according to multiple medical and lifestyle factors.
Do I still need to diet and exercise while taking semaglutide?
Yes. FDA-approved semaglutide for chronic weight management is intended to be used together with a reduced-calorie diet and increased physical activity.
What are the most common side effects?
Common side effects may include nausea, diarrhea, vomiting, constipation, abdominal discomfort, indigestion, bloating, headache, and fatigue. Contact your provider if symptoms are severe or persistent.
Can I take semaglutide if I have diabetes?
Some patients with type 2 diabetes may receive semaglutide, but medication selection and dosing require individualized medical evaluation. Blood glucose and other diabetes medications may require additional monitoring.
Can I use semaglutide during pregnancy?
Semaglutide should not be used for weight reduction during pregnancy. WEGOVY® prescribing information recommends stopping treatment at least two months before a planned pregnancy.
Will I regain weight if I stop semaglutide?
Weight regain can occur after treatment is discontinued. Long-term nutrition, activity, behavioral strategies, and medical follow-up are important components of weight management.
Is compounded semaglutide FDA-approved?
No. Compounded semaglutide products are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness, or quality. Patients should discuss the specific medication being prescribed with their healthcare provider.
Who should not take semaglutide?
WEGOVY® is contraindicated in patients with a personal or family history of medullary thyroid carcinoma, patients with MEN 2, and patients with a serious hypersensitivity to semaglutide or its ingredients. Other medical conditions may also affect treatment suitability.
Schedule a Semaglutide Weight Management Consultation in Mason, Ohio
If you are interested in medically supervised weight management, schedule a consultation at Regenerative Aesthetics in Mason, Ohio.
Our team will review your health history, current medications, weight-related concerns, previous weight-loss efforts, and individual goals to determine whether semaglutide or another medical weight-management option may be appropriate for you.
Regenerative Aesthetics
969 Reading Rd N
Mason, OH 45040
Phone: (513) 204-4483
Email: contact@regenspa.org